fexinidazole: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi	FEXINIDAZOLE	fexinidazole	TABLET;ORAL	214429	NDA	Sanofi-Aventis U.S. LLC	0024-4512-14	14 TABLET in 1 DOSE PACK (0024-4512-14)	2021-07-16
Sanofi	FEXINIDAZOLE	fexinidazole	TABLET;ORAL	214429	NDA	Sanofi-Aventis U.S. LLC	0024-4512-24	24 TABLET in 1 DOSE PACK (0024-4512-24)	2021-07-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key suppliers for fexinidazole, an antiparasitic medication approved for the treatment of human African trypanosomiasis (HAT) and Chagas disease. The analysis details manufacturing capabilities, geographical presence, and regulatory compliance relevant to API (Active Pharmaceutical Ingredient) and finished drug product production.

What is Fexinidazole?

Fexinidazole is a nitroimidazole derivative that functions as an antiparasitic agent. It is orally administered and has demonstrated efficacy against Trypanosoma brucei gambiense, the causative agent of late-stage HAT, and Trypanosoma cruzi, the parasite responsible for Chagas disease [1]. The World Health Organization (WHO) recommends fexinidazole as a first-line treatment for T. b. gambiense HAT, marking a significant advancement in the management of this neglected tropical disease [2]. Its development was a collaborative effort involving DNDi (Drugs for Neglected Diseases initiative) and Sanofi [3].

Active Pharmaceutical Ingredient (API) Manufacturing

The production of fexinidazole API is a critical stage in its supply chain. Several entities possess the technical expertise and regulatory standing to manufacture this complex molecule.

Key API Manufacturers

Sanofi: As a primary developer and marketer of fexinidazole, Sanofi has direct involvement in its API production. Sanofi's global manufacturing network includes facilities capable of producing pharmaceutical ingredients under stringent Good Manufacturing Practice (GMP) standards.
Contract Manufacturing Organizations (CMOs): Specialized CMOs with experience in complex organic synthesis are likely involved in the production of fexinidazole API. These organizations operate under strict quality control protocols and are often audited by pharmaceutical companies and regulatory bodies. Identification of specific CMOs often requires direct engagement with the drug developer or analysis of regulatory filings for manufacturing site registrations.

Regulatory Compliance for API Production

API manufacturers must adhere to international regulatory standards.

Good Manufacturing Practices (GMP): Compliance with GMP, as defined by the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national regulatory authorities, is mandatory. This ensures the quality, purity, and consistency of the API.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls of the API. While not publicly disclosed, the existence of a DMF indicates a supplier's commitment to regulatory compliance.
Inspections: Manufacturing facilities are subject to periodic inspections by regulatory bodies to verify ongoing compliance with GMP.

Geographical Distribution of API Production

The geographical location of API manufacturing is influenced by cost, regulatory environment, and logistics. Historically, significant API production for global markets has been concentrated in:

Europe: Countries such as France, Germany, and Switzerland have a strong presence of pharmaceutical manufacturing.
North America: The United States also hosts numerous API manufacturing facilities.
Asia: India and China are major global suppliers of APIs due to cost efficiencies and established chemical synthesis capabilities. Companies in these regions must demonstrate adherence to international GMP standards to supply regulated markets.

Finished Drug Product (FDP) Manufacturing and Packaging

The conversion of fexinidazole API into a finished dosage form (tablets) and subsequent packaging is another crucial step.

Key FDP Manufacturers and Packagers

Sanofi: Sanofi is responsible for the formulation of fexinidazole into its final tablet form and packaging for distribution. The company utilizes its established global pharmaceutical manufacturing and packaging infrastructure.
Third-Party Logistics (3PL) Providers and Contract Packagers: For certain markets or specific distribution needs, Sanofi may partner with specialized 3PL providers and contract packaging companies. These entities handle the logistics, warehousing, and final packaging of the finished product according to regulatory and product specifications.

Regulatory Compliance for FDP Production

FDP manufacturers must also meet stringent regulatory requirements.

GMP for Finished Pharmaceuticals: Adherence to GMP specific to drug product manufacturing is essential. This covers formulation, tableting, coating, packaging, and labeling.
Marketing Authorization Holder (MAH): The MAH (e.g., Sanofi) is ultimately responsible for the quality and safety of the finished drug product placed on the market, regardless of where manufacturing occurs.
Batch Release Testing: Each batch of finished product undergoes rigorous testing before release to ensure it meets all quality specifications.

Geographical Distribution of FDP Production

Finished drug product manufacturing and packaging facilities are strategically located to serve key markets and optimize distribution networks.

Sanofi's Global Network: Sanofi operates manufacturing sites across Europe, North America, Latin America, and Asia, enabling localized production and supply.
Packaging and Labeling: Packaging and labeling operations may occur at dedicated sites or in conjunction with drug product manufacturing to accommodate regional language and regulatory requirements.

Supply Chain Considerations and Risk Mitigation

The fexinidazole supply chain, like any pharmaceutical supply chain, presents potential risks that require proactive management.

Supply Chain Risks

Single Sourcing: Reliance on a single supplier for API or critical intermediates can create vulnerabilities. Diversification of suppliers, where feasible, mitigates this risk.
Geopolitical Instability: Events such as trade disputes, political unrest, or natural disasters in key manufacturing regions can disrupt supply.
Regulatory Changes: Evolving regulatory requirements in manufacturing countries can impact compliance and production continuity.
Quality Control Failures: Any lapse in quality control at API or FDP manufacturing sites can lead to product recalls and supply shortages.
Logistical Challenges: Transportation delays, customs issues, and cold chain management (if applicable) can affect product availability.

Risk Mitigation Strategies

Supplier Qualification and Auditing: Rigorous qualification and regular auditing of all suppliers (API, intermediates, packaging) ensure adherence to quality and regulatory standards.
Dual Sourcing: Identifying and qualifying secondary suppliers for critical raw materials or APIs can provide a backup in case of disruption.
Inventory Management: Maintaining adequate safety stock of API and finished product at strategic locations buffers against short-term supply interruptions.
Supply Chain Visibility: Implementing technologies and processes to enhance visibility across the entire supply chain allows for early detection of potential issues.
Contingency Planning: Developing robust contingency plans for various disruption scenarios, including alternative manufacturing sites or transport routes.
Long-Term Contracts: Securing long-term supply agreements with key partners provides stability and predictable pricing.

Key Companies Involved in the Fexinidazole Ecosystem

While Sanofi is the primary developer and marketer, a broader ecosystem supports the availability of fexinidazole.

Sanofi: Pharmaceutical company responsible for R&D, manufacturing, and commercialization.
DNDi (Drugs for Neglected Diseases initiative): Non-profit organization that played a crucial role in the R&D and access strategies for fexinidazole. DNDi works with manufacturers and partners to ensure drug availability for neglected diseases [3].
Contract Research Organizations (CROs): Involved in clinical trials and regulatory affairs.
Contract Manufacturing Organizations (CMOs): Potentially involved in API synthesis or specific manufacturing steps.
Logistics Providers: For global distribution and warehousing.

Market Dynamics and Access

The market for fexinidazole is largely driven by public health initiatives and the burden of neglected tropical diseases.

Neglected Tropical Diseases (NTDs): Fexinidazole's primary application is in treating HAT and Chagas disease, which disproportionately affect low-income populations in endemic regions of sub-Saharan Africa and Latin America.
WHO Procurement: The WHO is a significant procurer of fexinidazole for distribution to countries where HAT is endemic. This often involves bulk purchasing and direct allocation to national health programs.
Access Programs: DNDi and Sanofi have collaborated on access programs to ensure that fexinidazole is available to patients at an affordable price in the regions where it is needed most [3].

Regulatory Landscape

The approval and ongoing supply of fexinidazole are governed by health authorities worldwide.

European Medicines Agency (EMA): Granted marketing authorization for fexinidazole (marketed as Jabari®) in 2023 for the treatment of late-stage gambiense HAT [4].
U.S. Food and Drug Administration (FDA): While fexinidazole is not yet approved by the FDA for commercial sale in the U.S., the agency's guidelines on GMP and drug manufacturing are globally influential.
National Regulatory Authorities: Approval and import licenses are required from national regulatory authorities in each country where fexinidazole is distributed.

Future Outlook

The long-term supply of fexinidazole will depend on sustained demand, ongoing public health investment in NTD control, and the continued robustness of its manufacturing and distribution network.

Increased Demand: As awareness and diagnostic capabilities for HAT and Chagas disease improve, demand for effective treatments like fexinidazole may increase.
Manufacturing Efficiency: Efforts to optimize manufacturing processes and reduce production costs could further enhance access.
New Indications: While currently focused on HAT and Chagas, research into other parasitic or infectious diseases could potentially expand fexinidazole's therapeutic scope, influencing future supply chain needs.

Key Takeaways

Sanofi is the primary developer and marketer of fexinidazole, with direct involvement in API and finished drug product manufacturing.
Contract Manufacturing Organizations (CMOs) are likely key partners for fexinidazole API production, operating under stringent GMP standards.
Regulatory compliance, particularly adherence to Good Manufacturing Practices (GMP) by all manufacturing entities, is paramount for ensuring drug quality and global market access.
Geographical diversification of manufacturing capabilities across Europe, North America, and Asia is typical for pharmaceutical ingredients and finished products.
Supply chain resilience is critical, with strategies like supplier auditing, dual sourcing, and robust inventory management employed to mitigate risks.
The World Health Organization (WHO) is a major procurer, driving demand and distribution for fexinidazole in endemic regions for neglected tropical diseases.

Frequently Asked Questions

What is the primary manufacturing location for fexinidazole API?

Specific manufacturing locations for fexinidazole API are proprietary. However, production typically occurs in facilities adhering to international GMP standards, which are found in regions including Europe, North America, India, and China.

How does the WHO ensure a stable supply of fexinidazole?

The WHO procures fexinidazole through partnerships with Sanofi and DNDi, often utilizing bulk purchase agreements and direct distribution to national health programs in endemic countries. This ensures availability for public health initiatives.

Are there alternative suppliers for fexinidazole API besides Sanofi's direct manufacturing?

While Sanofi is the originator and likely has significant internal manufacturing capacity, it is common for pharmaceutical companies to utilize Contract Manufacturing Organizations (CMOs) for API production. Identifying these specific CMOs would require direct inquiry or review of detailed regulatory filings.

What regulatory hurdles must suppliers overcome to produce fexinidazole for global markets?

Suppliers must achieve and maintain compliance with Good Manufacturing Practices (GMP) as stipulated by regulatory bodies such as the EMA and FDA. This involves rigorous quality control, process validation, and successful facility inspections. Submission of Drug Master Files (DMFs) is also a standard requirement.

How does Sanofi manage the supply chain for a drug like fexinidazole, which targets neglected tropical diseases?

Sanofi manages the supply chain through its global manufacturing network, adherence to stringent quality controls, and collaboration with organizations like DNDi. Risk mitigation strategies include supplier qualification, inventory management, and contingency planning to ensure consistent availability, particularly for access programs targeting low-income populations.

Suppliers and packagers for fexinidazole

fexinidazole

Fexinidazole Supply Chain Analysis